The work can be both in vivo or ex vivo, meaning inside or outside an organism.ĬRISPR technology is also being used to develop treatments for unmet diseases. They include editing stem cells or T cells to create better stem cells, such as chimeric antigen receptor T cells, better known as CAR-Ts, for use in immunotherapy. Use cases for CRISPR depend on what the molecule is capable of, Oakes said. He added: “By accelerating the shift from an artisanal discovery approach to a fully industrialized one, the company is poised to fundamentally transform how we treat and manage genetic diseases at scale.” Use cases Meanwhile, Vijay Pande, general partner at Andreessen Horowitz, said in a statement that Scribe’s approach has “revolutionized industry expectations for blueprinting and creating CRISPR-based therapies.” “Scribe is applying deep, multidisciplinary engineering expertise to develop the custom tools and applications needed to confront genetic diseases,” said Aghazadeh in a written statement. Gordon, managing partner at OrbiMed Advisors, will join Scribe’s board of directors. To date, the company raised $120 million, which includes a $20 million Series A round in 2018 led by Andreessen Horowitz, according to Crunchbase data.Īs part of the financing, Behzad Aghazadeh, managing partner at Avoro Ventures and Avoro Capital Advisors, and Carl L. Rowe Price Associates, and funds managed by Wellington Management, RA Capital Management and Menlo Ventures. The syndicate also includes Perceptive Advisors, funds and accounts advised by T. “I was spending 90 hours a week testing, so you can see immediately why CRISPR would be impactful.” Treating diseaseĪvoro Ventures and an affiliated company, Avoro Capital Advisors, led the Series B financing and were joined by OrbiMed Advisors and Andreessen Horowitz. “I started in genome editing a decade ago, and the only way to do this was to build a library of molecules and test every one over and over again,” Oakes said. Scribe was founded “on paper” in 2017 by molecular engineers Benjamin Oakes, Brett Staahl and David Savage, as well as CRISPR co-inventor Jennifer Doudna, who won the 2020 Nobel Prize in chemistry, to create advanced technologies for CRISPR-based genetic medicine.ĬRISPR stands for “ clustered regularly interspaced short palindromic repeats” and enables researchers to more easily identify DNA sequences and modify gene function to develop in vivo therapies that treat the underlying cause of disease, Oakes told Crunchbase News. To learn more about Scribe’s mission to rewrite the story of disease, visit engineering company Scribe Therapeutics has completed an oversubscribed $100 million round of Series B financing to further develop its “CRISPR by design” platform, as well as advance its pipeline of genetic treatments. The company is backed by leading individual and institutional investors including Andreessen Horowitz. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. Scribe Therapeutics is a molecular engineering company focused on building best-in-class in vivo therapies to permanently treat the underlying cause of disease. Scribe is also eligible to receive tiered, high single digit to sub-teen royalties. Scribe will receive $15 million upfront and is eligible for more than $400 million in potential development and commercial milestone payments between the two targets of interest. Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need. “We’re proud to collaborate with Biogen and apply our uniquely customized approaches with the goal of developing new, safe and effective genetic medicines for neurodegenerative disease.” “Scribe has designed, engineered and tested thousands of evolved CRISPR enzymes to build an advanced platform for creating breakthrough in vivo treatments,” said Benjamin Oakes, CEO and co-founder of Scribe Therapeutics. The company’s first technology, X-Editing (XE), provides greater editing activity, specificity and deliverability than other CRISPR genome editing tools currently available. Scribe’s platform is focused on engineering, delivering, and developing novel, custom CRISPR molecules. (Nasdaq:BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS). ALAMEDA, Calif.-( BUSINESS WIRE)-Scribe Therapeutics Inc., the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, today announced a research collaboration with Biogen Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |